BR112012020839A2 - vacinas para uso na profilaxe e tratamento de doença de vírus da influenza - Google Patents

vacinas para uso na profilaxe e tratamento de doença de vírus da influenza

Info

Publication number
BR112012020839A2
BR112012020839A2 BR112012020839A BR112012020839A BR112012020839A2 BR 112012020839 A2 BR112012020839 A2 BR 112012020839A2 BR 112012020839 A BR112012020839 A BR 112012020839A BR 112012020839 A BR112012020839 A BR 112012020839A BR 112012020839 A2 BR112012020839 A2 BR 112012020839A2
Authority
BR
Brazil
Prior art keywords
vaccines
influenza virus
prophylaxis
treatment
virus disease
Prior art date
Application number
BR112012020839A
Other languages
English (en)
Portuguese (pt)
Inventor
Garcia-Sastre Adolfo
S Tan Gene
Palese Peter
T Wang Taia
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/788,103 external-priority patent/US8673314B2/en
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of BR112012020839A2 publication Critical patent/BR112012020839A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012020839A 2010-02-18 2011-02-18 vacinas para uso na profilaxe e tratamento de doença de vírus da influenza BR112012020839A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30589810P 2010-02-18 2010-02-18
US12/788,103 US8673314B2 (en) 2009-05-26 2010-05-26 Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US35416010P 2010-06-11 2010-06-11
US38508310P 2010-09-21 2010-09-21
PCT/US2011/025467 WO2011103453A2 (en) 2010-02-18 2011-02-18 Vaccines for use in the prophylaxis and treatment of influenza virus disease

Publications (1)

Publication Number Publication Date
BR112012020839A2 true BR112012020839A2 (pt) 2017-11-21

Family

ID=44483593

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020839A BR112012020839A2 (pt) 2010-02-18 2011-02-18 vacinas para uso na profilaxe e tratamento de doença de vírus da influenza

Country Status (10)

Country Link
US (1) US9701723B2 (enExample)
EP (1) EP2536425B1 (enExample)
JP (3) JP2013520172A (enExample)
KR (1) KR20120132506A (enExample)
CN (1) CN102939096B (enExample)
AU (1) AU2011217903B2 (enExample)
BR (1) BR112012020839A2 (enExample)
CA (1) CA2790380A1 (enExample)
MX (1) MX342716B (enExample)
WO (1) WO2011103453A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR101768600B1 (ko) * 2015-05-18 2017-08-17 한국생명공학연구원 범용성 개 인플루엔자 바이러스 백신 조성물
JP6868763B2 (ja) * 2016-04-01 2021-05-12 パナソニックＩｐマネジメント株式会社 インフルエンザウィルスに結合する抗体
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US10478488B2 (en) 2017-10-03 2019-11-19 Southwest Research Institute Liposomal flu vaccine formulation
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
RU2757013C2 (ru) * 2017-12-19 2021-10-08 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения
CN108287235B (zh) * 2018-02-07 2021-03-09 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用
CN108329379B (zh) * 2018-04-08 2022-01-28 诺华生物科技（武汉）有限责任公司 H7亚型流感病毒h7n9的普通型/嵌合型病毒样颗粒及制备方法、应用和疫苗
CN108840911B (zh) * 2018-06-09 2021-03-30 西北农林科技大学 新城疫病毒基质蛋白的抗原表位、抗体、鉴定方法和应用
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12059462B2 (en) 2018-07-23 2024-08-13 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
CN111363017B (zh) * 2018-12-25 2022-03-15 中国科学院微生物研究所 A型流感病毒核蛋白s69位突变序列及其突变体与应用
TWI857017B (zh) * 2019-03-04 2024-10-01 國立感染症研究所長代表之日本國 流感ha裂解疫苗之製造方法
CA3132578A1 (en) 2019-03-04 2020-09-10 Japan As Represented By Director General Of National Institute Of Infectious Diseases Method for producing influenza ha split vaccine
CN111134250A (zh) * 2019-12-03 2020-05-12 海南大学 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法
CN111298098B (zh) * 2020-02-25 2021-10-29 中国科学院微生物研究所 卡泊芬净在制备抑制冠状病毒的产品中的应用
EP4120863A4 (en) * 2020-03-19 2024-04-24 Renibus Therapeutics, Inc. METHOD FOR TREATING CORONAVIRUS INFECTION
CN117229370B (zh) * 2022-06-08 2024-11-01 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用
WO2024097396A1 (en) * 2022-11-05 2024-05-10 Us Biologic, Inc. Visco-elastic solid formulation for oral delivery of a biologically active agent
WO2025106608A2 (en) * 2023-11-15 2025-05-22 Red Queen Therapeutics, Inc. Antiviral structurally stapled influenza peptides and uses thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) * 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994016109A1 (en) * 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) * 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
ES2262514T3 (es) 1999-04-29 2006-12-01 Syngenta Limited Plantas resistentes a herbicidas.
MXPA02003069A (es) * 1999-09-24 2002-09-30 Smithkline Beecham Biolog Vacuna intranasal contra el virus de la influenza..
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6951754B2 (en) * 2000-04-28 2005-10-04 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
ES2563402T3 (es) 2002-02-13 2016-03-15 Wisconsin Alumni Research Foundation Señal para el empaquetamiento de vectores del virus de la gripe
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2004067553A2 (en) 2003-01-29 2004-08-12 The Research Foundation Of The State University Of New York Tolerance-induced targeted antibody production
DE602004020189D1 (de) * 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
JP4368594B2 (ja) * 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
WO2004098533A2 (en) 2003-05-05 2004-11-18 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
PL2261377T3 (pl) * 2003-11-04 2014-03-31 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
AU2005248375B2 (en) * 2004-05-25 2010-12-16 Medimmune, Llc Influenza hemagglutinin and neuraminidase varians
EP1851238A4 (en) * 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
NZ568211A (en) * 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
ATE552846T1 (de) * 2005-12-06 2012-04-15 Yeda Res & Dev Verbesserter grippeimpfstoff
US10183986B2 (en) * 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
EP2023952B1 (en) 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
ES2428067T3 (es) 2006-07-21 2013-11-05 California Institute Of Technology Introducción selectiva de genes para la vacunación con células dendríticas
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
EP2174957B1 (en) * 2007-06-15 2016-03-16 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2014279A1 (en) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009025770A2 (en) 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
WO2009088401A2 (en) * 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2238253B1 (en) 2007-11-27 2012-09-12 Medicago Inc. Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
US20110038935A1 (en) 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2540740B1 (en) * 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
EP2695941B1 (en) 2008-06-25 2015-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel immunoadjuvant flagellin-based compounds and use thereof
CA2730171C (en) 2008-07-08 2016-10-11 Medicago Inc. Soluble recombinant influenza antigens
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
US8673314B2 (en) * 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
NZ597401A (en) 2009-06-24 2013-09-27 Medicago Inc Chimeric influenza virus-like particles comprising hemagglutinin
CA2805505C (en) * 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
JP5463107B2 (ja) 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
MX338758B (es) 2010-03-08 2016-04-29 Celltrion Inc Anticuerpos monoclonales humanos, derivados de celulas b humanas, y que tienen actividad neutralizante contra el virus de la influenza a.
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
ES2739711T3 (es) 2010-07-22 2020-02-03 John W Schrader Anticuerpo de protección cruzada contra la infección por el virus de la gripe
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
WO2014090865A1 (en) 2012-12-11 2014-06-19 Vib Vzw Anti-influenza antibody
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
MX2012009581A (es) 2013-01-29
CN102939096A (zh) 2013-02-20
EP2536425B1 (en) 2019-06-19
JP2016196472A (ja) 2016-11-24
US20170114103A9 (en) 2017-04-27
EP2536425A4 (en) 2014-11-05
US9701723B2 (en) 2017-07-11
AU2011217903A1 (en) 2012-09-13
CN102939096B (zh) 2016-03-02
WO2011103453A2 (en) 2011-08-25
JP2013520172A (ja) 2013-06-06
AU2011217903B2 (en) 2017-03-02
EP2536425A2 (en) 2012-12-26
CA2790380A1 (en) 2011-08-25
WO2011103453A3 (en) 2011-12-29
US20130209499A1 (en) 2013-08-15
MX342716B (es) 2016-10-11
KR20120132506A (ko) 2012-12-05
JP2018166515A (ja) 2018-11-01

Similar Documents

Publication Publication Date Title
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2016000381A1 (es) Compuestos antivirales
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
UY32457A (es) Vacuna del virus del dengue inactivado
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2014001599A1 (es) Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc).
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112014021065A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor
MX2017003117A (es) Particula tipo virus de flavivirus.
BR112014021068A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
BR112017011476A2 (pt) composição baseada em aminoácidos para recuperação de fibroelastina em tecidos conjuntivos dérmicos e uso
CL2016000300A1 (es) Métodos terapéuticos

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained